Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Simulation-Free Single-Fraction Radiation Therapy for Indolent Lymphoma (SIMPLY)

15. november 2026 oppdatert av: University Health Network, Toronto

SIMulation-free Protocols for Lymphoma RadiotherapY [SIMPLY]

This pilot study will evaluate whether people with indolent B-cell lymphoma can receive radiation therapy without a separate computed tomography (CT) simulation appointment. Participants will receive one low-dose radiation treatment of 4 gray (Gy). Treatment planning will use a recent diagnostic CT scan, and cone-beam computed tomography (CBCT) imaging on the treatment day will be used to confirm participant positioning and adjust the treatment plan if needed.

The study includes participants with orbital or ocular adnexal lymphoma and participants with lymphoma at other body sites. The investigators will assess whether simulation-free treatment can be completed successfully, treatment duration, the number of hospital visits required, treatment side effects, patient-reported symptoms, control of the treated lymphoma site, and the need for additional treatment. Participants will be followed for up to 12 months.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

This prospective, single-centre, single-arm pilot feasibility study evaluates a simulation-free, cone-beam computed tomography (CBCT)-guided adaptive radiation therapy workflow for participants with indolent B-cell lymphoma.

Participants will receive single-fraction ultra-low-dose radiation therapy consisting of 4 Gy delivered in one treatment session. Instead of undergoing a separate CT simulation, treatment planning will use a recent diagnostic CT scan suitable for contouring and dose calculation.

On the treatment day, CBCT imaging will be obtained to confirm participant positioning and anatomy. The treatment plan may be adapted while the participant is on the treatment couch and will be reviewed and approved before radiation delivery.

The study includes two cohorts:

Participants with orbital or ocular adnexal indolent B-cell lymphoma.

Participants with non-orbital indolent B-cell lymphoma.

If an acceptable simulation-free treatment plan cannot be produced, the participant will proceed through the standard CT simulation-based treatment process. This will be recorded as an unsuccessful simulation-free workflow but will not prevent the participant from receiving clinically appropriate treatment.

The primary objective is to determine the proportion of participants who successfully complete treatment without requiring conventional CT simulation.

Secondary assessments include treatment timing, on-couch time, hospital visits avoided, reasons for workflow failure, treatment-related side effects, patient-reported symptoms, local control of the treated site at 6 months, and retreatment of the treated site within 12 months.

Studietype

Intervensjonell

Registrering (Antatt)

60

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Ontario
      • Toronto, Ontario, Canada, M5G 1X6
        • Rekruttering
        • Princess Margaret Cancer Centre, University Health Network
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Barn
  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Histologically confirmed indolent B-cell lymphoma, including marginal zone/mucosa-associated lymphoid tissue (MALT) lymphoma, follicular lymphoma grades 1-2, small lymphocytic lymphoma, or mantle cell lymphoma.
  • Disease requiring focal radiation therapy with 4 Gy delivered in one fraction for local control or symptom relief.
  • Lesion anatomy suitable for single-fraction radiation therapy and simulation-free, CBCT-guided treatment delivery, as determined by the treating radiation oncologist.
  • Available diagnostic CT imaging suitable for contouring and dose calculation that encompasses the full intended target and relevant organs at risk:
  • Obtained within 2 months before treatment for orbital or ocular adnexal disease.
  • Obtained within 6 weeks before treatment for non-orbital disease.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-3, with the ability to tolerate treatment positioning and delivery.
  • Localized or advanced-stage disease is permitted, provided the target lesion is appropriate for focal treatment.

Exclusion Criteria:

  • Diagnostic imaging that does not meet the minimum quality requirements for treatment planning or falls outside the required time window.
  • Disease anatomy unsuitable for simulation-free delivery, such as inability to maintain stable positioning, excessive motion, or inadequate CBCT visualization.
  • Prior radiation therapy to the same site if re-irradiation using the study workflow is considered clinically inappropriate.
  • Bulky disease greater than 6 centimeters for which single-fraction 4 Gy radiation therapy is unlikely to provide adequate local control, as determined by the treating physician.
  • Requirement for urgent systemic therapy because of widespread or symptomatic disease.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Simulation-Free Single-Fraction Radiation Therapy

Participants will receive simulation-free, cone-beam computed tomography (CBCT)-guided adaptive radiation therapy delivered as a single 4 gray (Gy) fraction. Treatment planning will use a recent diagnostic computed tomography (CT) scan instead of a separate planning CT simulation. CBCT imaging will be obtained on the treatment day to confirm positioning and anatomy and to adapt the treatment plan when needed. Participants for whom the simulation-free workflow is not feasible will proceed to standard CT simulation-based treatment.

Participants will receive a single 4 gray (Gy) fraction of radiation therapy using a simulation-free workflow. A recent diagnostic computed tomography (CT) scan suitable for contouring and dose calculation will be used for initial treatment planning instead of a separate planning CT simulation. On the treatment day, cone-beam computed tomography (CBCT) imaging will be obtained to confirm positioning and anatomy. The treatment plan may be adapted on the treatment couch and will undergo physician and physics review before radiation is delivered. If a clinically acceptable simulation-free plan cannot be produced, the participant will proceed to the standard CT simulation-based workflow.

Andre navn:
  • Ultra-Low-Dose Radiation Therapy
  • CBCT-Guided Adaptive Radiation Therapy
  • Diagnostic CT-Based Radiation Treatment Planning

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Successful Completion of Simulation-Free Radiation Therapy
Tidsramme: Periprocedural (single radiation treatment session)

Proportion of participants who successfully complete the prescribed single-fraction 4 Gy radiation treatment using the simulation-free, cone-beam CT-guided adaptive workflow without requiring fallback to conventional CT simulation. The workflow will be considered feasible if at least 80% of participants complete treatment without conventional CT simulation.

Periprocedural (single radiation treatment session)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Time From Radiation Oncology Consultation to Treatment
Tidsramme: From radiation oncology consultation to initiation of radiotherapy, up to 4 weeks

Number of calendar days between the radiation oncology consultation date and the date of radiation treatment.

From radiation oncology consultation to initiation of radiotherapy, up to 4 weeks
Same-Day Treatment
Tidsramme: Day 1 (date of radiation oncology consultation)

Proportion of participants who receive radiation treatment on the same calendar day as their radiation oncology consultation.

Day 1 (date of radiation oncology consultation)
Total On-Couch Time
Tidsramme: Periprocedural (single radiation treatment session)

Total number of minutes the participant spends on the treatment couch, measured from initial positioning to completion of radiation delivery.

Periprocedural (single radiation treatment session)
Number of Hospital Visits
Tidsramme: From referral to Radiation Oncology through completion of radiation treatment, up to 4 weeks

Number of hospital visits occurring between referral to Radiation Oncology and completion of radiation treatment. The observed number will be used to estimate visits avoided compared with the conventional CT simulation-based workflow.

From referral to Radiation Oncology through completion of radiation treatment, up to 4 weeks
CT Simulation Avoided
Tidsramme: Periprocedural (through completion of the single radiation treatment session)

Proportion of participants who complete radiation treatment without requiring a separate conventional CT simulation appointment.

Periprocedural (through completion of the single radiation treatment session)
Reasons for Simulation-Free Workflow Failure
Tidsramme: From treatment planning through radiation treatment completion, up to 4 weeks

Reasons that the simulation-free workflow could not be completed, including inadequate diagnostic imaging, changes in anatomy, positioning difficulties, inadequate cone-beam CT visualization, or inability to produce an acceptable treatment plan.

From treatment planning through radiation treatment completion, up to 4 weeks
Clinician-Graded Treatment-Related Toxicity
Tidsramme: Baseline, 2-4 weeks, and 3 months after treatment

Incidence and severity of treatment-related adverse events assessed using the Common Terminology Criteria for Adverse Events, version 5.0. The proportions of participants experiencing Grade 2 or higher and Grade 3 or higher events will be reported.

Baseline, 2-4 weeks, and 3 months after treatment
Ocular Surface Disease Index Score
Tidsramme: Baseline, 2-4 weeks, and 3 months after treatment

Change in Ocular Surface Disease Index score among participants with orbital or ocular adnexal lymphoma. Higher scores indicate greater ocular-surface-related symptoms and functional impairment.

Baseline, 2-4 weeks, and 3 months after treatment
Head and Neck Quality-of-Life Symptoms
Tidsramme: Baseline, 2-4 weeks, and 3 months after treatment

Change in relevant patient-reported symptoms measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck 43 among applicable participants with head-and-neck treatment sites.

Baseline, 2-4 weeks, and 3 months after treatment
Index Symptom Severity
Tidsramme: Baseline, 2-4 weeks, and 3 months after treatment

Change in the participant's main treatment-related symptom measured using a numeric rating scale from 0 to 10, where 0 indicates no symptom and 10 indicates the worst imaginable symptom.

Baseline, 2-4 weeks, and 3 months after treatment
Local Control of the Treated Site
Tidsramme: 6 months after radiation treatment

Proportion of participants without radiographic or clinical progression within the irradiated site. Local control will be determined using the best routinely available assessment modality, which may include PET/CT, CT, MRI, ophthalmologic assessment, or clinical examination.

6 months after radiation treatment
Retreatment of the Treated Site
Tidsramme: Within 12 months after radiation treatment

Proportion of participants who require additional local or systemic treatment for inadequate response or progression at the irradiated site.

Within 12 months after radiation treatment

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

9. oktober 2026

Primær fullføring (Antatt)

31. desember 2028

Studiet fullført (Antatt)

31. desember 2028

Datoer for studieregistrering

Først innsendt

27. oktober 2026

Først innsendt som oppfylte QC-kriteriene

15. november 2026

Først lagt ut (Faktiske)

18. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

15. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 26-5319

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .